- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00738543
Povidone-iodine Against Sodium Hypochlorite as Skin Antiseptics
June 18, 2013 updated by: Alejandro E. Macias, Universidad de Guanajuato
Comparative Study of 10% Povidone-iodine Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers.
The investigators have few options for skin antisepsis.
Alternatives for povidone-iodine, which is the most commonly used agent, are costly or ineffective.
To have more options, this study is needed.
The investigators want to know if there are difference between the use of 10% sodium hypochlorite or 10% povidone-iodine for skin antisepsis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Sodium hypochlorite at 10% has been widely used as antiseptic in patients on dialysis as well as for irrigation of wounds and burns.
Since it has been used successfully in caring for the exit site of hemodialysis catheters, it is reasonable to propose its use for the insertion and care of central intravascular catheters, as well as for skin preparation before surgery.
Alternatives for povidone-iodine, which is the agent most commonly used, are costly or ineffective.
To have more options, this study is needed to know if 10% sodium hypochlorite is similar to the most common option for skin antisepsis.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guanajuato
-
Leon, Guanajuato, Mexico, 37000
- University of Guanajuato School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult volunteers.
Exclusion Criteria:
- History of skin allergies or atopy, as well as reactions to soaps, iodine, chlorine, or latex
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Whole group of 48 volunteers
The arm is composed of 48 human volunteers to test 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City), Hypochlorite 10% of electrochemical production (Exsept 10% ®, Pisa, Guadalajara, Mexico), and control.
|
Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics.
The intervention consisted of preparing the skin with the antiseptic or the control.
The areas were approximately 25 cm2 on the forearm for each antiseptic or control.
The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution.
The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted.
All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacterial Count of Skin Cultures for the 10% Povidone-iodine Period
Time Frame: 24 hours
|
Bacterial colony count of skin cultures to determine antiseptic properties
|
24 hours
|
Bacterial Colony Forming Units for the 10% Sodium Hypochlorite Period
Time Frame: 24 hours
|
After incubation, the outcome assessor counted the colonies to determine the colony-forming units per square centimeter (CFU/cm2) of skin.
|
24 hours
|
Bacterial Colony Forming Units for the Control Period
Time Frame: 24 hours
|
After incubation, the outcome assessor counted the colonies to determine the colony-forming units per square centimeter (CFU/cm2) of skin.
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of Skin Reactions for the 10% Povidone-iodine Period
Time Frame: 24 hours
|
Presence of allergy or any skin reaction at 24 hours after the antiseptic application
|
24 hours
|
Presence af Allergy or Skin Reaction for the 10% Sodium Hypochlorite Period
Time Frame: 24 hours
|
Presence of allergy or skin reaction at 24 hours after the application of the antiseptic
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alejandro E Macias, M. D., Universidad de Guanajuato
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
August 18, 2008
First Submitted That Met QC Criteria
August 19, 2008
First Posted (Estimate)
August 20, 2008
Study Record Updates
Last Update Posted (Estimate)
June 24, 2013
Last Update Submitted That Met QC Criteria
June 18, 2013
Last Verified
February 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMUGAmuch
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on WHOLE GROUP OF 48 VOLUNTEERS
-
Magdi Yacoub Heart FoundationRecruitingGenetic Predisposition to DiseaseEgypt
-
Karadeniz Technical UniversityCompleted
-
University of Novi SadCompleted
-
Eastern Mediterranean UniversityCompletedLumbar Disc HerniationCyprus
-
Chumakov Federal Scientific Center for Research...RecruitingCoronavirus Infections | VaccineRussian Federation
-
Universidad Miguel Hernandez de ElcheUniversity of SevilleCompleted
-
Oregon Health and Science UniversityCompletedObesity | Weight GainUnited States
-
Cairo UniversityRecruitingPatellofemoral Pain SyndromeEgypt
-
Cairo UniversityEnrolling by invitation
-
University of AarhusAarhus University Hospital; Regionshospitalet Hammel Neurocenter; Roche Diagnostics and other collaboratorsCompletedCardiac ArrestDenmark, Norway